Structures of a minimal human CFTR first nucleotide-binding domain as a monomer, head-to-tail homodimer, and pathogenic mutant
Upon removal of the regulatory insert (RI), the first nucleotide binding domain (NBD1) of human cystic fibrosis transmembrane conductance regulator (CFTR) can be heterologously expressed and purified in a form that remains stable without solubilizing mutations, stabilizing agents or the regulatory e...
Saved in:
Published in | Protein engineering, design and selection Vol. 23; no. 5; pp. 375 - 384 |
---|---|
Main Authors | , , , , , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
England
Oxford University Press
01.05.2010
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Upon removal of the regulatory insert (RI), the first nucleotide binding domain (NBD1) of human cystic fibrosis transmembrane conductance regulator (CFTR) can be heterologously expressed and purified in a form that remains stable without solubilizing mutations, stabilizing agents or the regulatory extension (RE). This protein, NBD1 387–646(Δ405–436), crystallizes as a homodimer with a head-to-tail association equivalent to the active conformation observed for NBDs from symmetric ATP transporters. The 1.7-Å resolution X-ray structure shows how ATP occupies the signature LSGGQ half-site in CFTR NBD1. The ΔF508 version of this protein also crystallizes as a homodimer and differs from the wild-type structure only in the vicinity of the disease-causing F508 deletion. A slightly longer construct crystallizes as a monomer. Comparisons of the homodimer structure with this and previously published monomeric structures show that the main effect of ATP binding at the signature site is to order the residues immediately preceding the signature sequence, residues 542–547, in a conformation compatible with nucleotide binding. These residues likely interact with a transmembrane domain intracellular loop in the full-length CFTR channel. The experiments described here show that removing the RI from NBD1 converts it into a well-behaved protein amenable to biophysical studies yielding deeper insights into CFTR function. |
---|---|
AbstractList | Upon removal of the regulatory insert (RI), the first nucleotide binding domain (NBD1) of human cystic fibrosis transmembrane conductance regulator (CFTR) can be heterologously expressed and purified in a form that remains stable without solubilizing mutations, stabilizing agents or the regulatory extension (RE). This protein, NBD1 387–646(Δ405–436), crystallizes as a homodimer with a head-to-tail association equivalent to the active conformation observed for NBDs from symmetric ATP transporters. The 1.7-Å resolution X-ray structure shows how ATP occupies the signature LSGGQ half-site in CFTR NBD1. The ΔF508 version of this protein also crystallizes as a homodimer and differs from the wild-type structure only in the vicinity of the disease-causing F508 deletion. A slightly longer construct crystallizes as a monomer. Comparisons of the homodimer structure with this and previously published monomeric structures show that the main effect of ATP binding at the signature site is to order the residues immediately preceding the signature sequence, residues 542–547, in a conformation compatible with nucleotide binding. These residues likely interact with a transmembrane domain intracellular loop in the full-length CFTR channel. The experiments described here show that removing the RI from NBD1 converts it into a well-behaved protein amenable to biophysical studies yielding deeper insights into CFTR function. Upon removal of the regulatory insert (RI), the first nucleotide binding domain (NBD1) of human cystic fibrosis transmembrane conductance regulator (CFTR) can be heterologously expressed and purified in a form that remains stable without solubilizing mutations, stabilizing agents or the regulatory extension (RE). This protein, NBD1 387-646(405-436), crystallizes as a homodimer with a head-to-tail association equivalent to the active conformation observed for NBDs from symmetric ATP transporters. The 1.7-Aa resolution X-ray structure shows how ATP occupies the signature LSGGQ half-site in CFTR NBD1. The F508 version of this protein also crystallizes as a homodimer and differs from the wild-type structure only in the vicinity of the disease-causing F508 deletion. A slightly longer construct crystallizes as a monomer. Comparisons of the homodimer structure with this and previously published monomeric structures show that the main effect of ATP binding at the signature site is to order the residues immediately preceding the signature sequence, residues 542-547, in a conformation compatible with nucleotide binding. These residues likely interact with a transmembrane domain intracellular loop in the full-length CFTR channel. The experiments described here show that removing the RI from NBD1 converts it into a well-behaved protein amenable to biophysical studies yielding deeper insights into CFTR function. Upon removal of the regulatory insert (RI), the first nucleotide binding domain (NBD1) of human cystic fibrosis transmembrane conductance regulator (CFTR) can be heterologously expressed and purified in a form that remains stable without solubilizing mutations, stabilizing agents or the regulatory extension (RE). This protein, NBD1 387-646(Delta405-436), crystallizes as a homodimer with a head-to-tail association equivalent to the active conformation observed for NBDs from symmetric ATP transporters. The 1.7-A resolution X-ray structure shows how ATP occupies the signature LSGGQ half-site in CFTR NBD1. The DeltaF508 version of this protein also crystallizes as a homodimer and differs from the wild-type structure only in the vicinity of the disease-causing F508 deletion. A slightly longer construct crystallizes as a monomer. Comparisons of the homodimer structure with this and previously published monomeric structures show that the main effect of ATP binding at the signature site is to order the residues immediately preceding the signature sequence, residues 542-547, in a conformation compatible with nucleotide binding. These residues likely interact with a transmembrane domain intracellular loop in the full-length CFTR channel. The experiments described here show that removing the RI from NBD1 converts it into a well-behaved protein amenable to biophysical studies yielding deeper insights into CFTR function. Upon removal of the regulatory insert (RI), the first nucleotide binding domain (NBD1) of human cystic fibrosis transmembrane conductance regulator (CFTR) can be heterologously expressed and purified in a form that remains stable without solubilizing mutations, stabilizing agents or the regulatory extension (RE). This protein, NBD1 387-646({Delta}405-436), crystallizes as a homodimer with a head-to-tail association equivalent to the active conformation observed for NBDs from symmetric ATP transporters. The 1.7-{angstrom} resolution X-ray structure shows how ATP occupies the signature LSGGQ half-site in CFTR NBD1. The {Delta}F508 version of this protein also crystallizes as a homodimer and differs from the wild-type structure only in the vicinity of the disease-causing F508 deletion. A slightly longer construct crystallizes as a monomer. Comparisons of the homodimer structure with this and previously published monomeric structures show that the main effect of ATP binding at the signature site is to order the residues immediately preceding the signature sequence, residues 542-547, in a conformation compatible with nucleotide binding. These residues likely interact with a transmembrane domain intracellular loop in the full-length CFTR channel. The experiments described here show that removing the RI from NBD1 converts it into a well-behaved protein amenable to biophysical studies yielding deeper insights into CFTR function. |
Author | Gheyi, Tarun Zhao, Xun Brouillette, Christie G. Conners, Kris Romero, Rich Emtage, Spencer Hendle, Jorg Weber, Patricia C. Hunt, John F. Guggino, William B. Wetmore, Diana Atwell, Shane Protasevich, Irina I. Wasserman, Stephen R. Rodgers, Logan A. Lu, Frances Zhang, Feiyu F. Lewis, Hal A. |
Author_xml | – sequence: 1 givenname: Shane surname: Atwell fullname: Atwell, Shane email: satwell@lilly.com, To whom correspondence should be addressed. satwell@lilly.com. organization: Eli Lilly & Co., 10300 Campus Point Drive, San Diego, CA 92121, USA – sequence: 2 givenname: Christie G. surname: Brouillette fullname: Brouillette, Christie G. organization: Department of Chemistry and – sequence: 3 givenname: Kris surname: Conners fullname: Conners, Kris organization: Eli Lilly & Co., 10300 Campus Point Drive, San Diego, CA 92121, USA – sequence: 4 givenname: Spencer surname: Emtage fullname: Emtage, Spencer organization: Eli Lilly & Co., 10300 Campus Point Drive, San Diego, CA 92121, USA – sequence: 5 givenname: Tarun surname: Gheyi fullname: Gheyi, Tarun organization: Eli Lilly & Co., 10300 Campus Point Drive, San Diego, CA 92121, USA – sequence: 6 givenname: William B. surname: Guggino fullname: Guggino, William B. organization: Department of Physiology, School of Medicine, The Johns Hopkins University, Baltimore, MD 21205, USA – sequence: 7 givenname: Jorg surname: Hendle fullname: Hendle, Jorg organization: Eli Lilly & Co., 10300 Campus Point Drive, San Diego, CA 92121, USA – sequence: 8 givenname: John F. surname: Hunt fullname: Hunt, John F. organization: Department of Biological Sciences, Columbia University, New York, NY 10027, USA – sequence: 9 givenname: Hal A. surname: Lewis fullname: Lewis, Hal A. organization: Present address: Department of Macromolecular Crystallography, Bristol-Myers Squibb, Princeton, NJ 08543, USA – sequence: 10 givenname: Frances surname: Lu fullname: Lu, Frances organization: Eli Lilly & Co., 10300 Campus Point Drive, San Diego, CA 92121, USA – sequence: 11 givenname: Irina I. surname: Protasevich fullname: Protasevich, Irina I. organization: Center for Biophysical Sciences and Engineering, University of Alabama at Birmingham, Birmingham, AL 35294, USA – sequence: 12 givenname: Logan A. surname: Rodgers fullname: Rodgers, Logan A. organization: Eli Lilly & Co., 10300 Campus Point Drive, San Diego, CA 92121, USA – sequence: 13 givenname: Rich surname: Romero fullname: Romero, Rich organization: Eli Lilly & Co., 10300 Campus Point Drive, San Diego, CA 92121, USA – sequence: 14 givenname: Stephen R. surname: Wasserman fullname: Wasserman, Stephen R. organization: Eli Lilly & Co., 10300 Campus Point Drive, San Diego, CA 92121, USA – sequence: 15 givenname: Patricia C. surname: Weber fullname: Weber, Patricia C. organization: Present address: Imiplex, Yardley, PA 19067, USA – sequence: 16 givenname: Diana surname: Wetmore fullname: Wetmore, Diana organization: Cystic Fibrosis Foundation Therapeutics, Bethesda, MD 20814, USA – sequence: 17 givenname: Feiyu F. surname: Zhang fullname: Zhang, Feiyu F. organization: Eli Lilly & Co., 10300 Campus Point Drive, San Diego, CA 92121, USA – sequence: 18 givenname: Xun surname: Zhao fullname: Zhao, Xun organization: Eli Lilly & Co., 10300 Campus Point Drive, San Diego, CA 92121, USA |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/20150177$$D View this record in MEDLINE/PubMed https://www.osti.gov/biblio/1002367$$D View this record in Osti.gov |
BookMark | eNqFkc9rFDEUx4NU7A-9epTgRYROm0wmk52jLLYrVAptBdlLeJu82Y3OJNskA-rBv72zzrrXnvIIn_f98r7fU3Lkg0dC3nJ2wVkjLrcxZHT-cv3nkbHqBTnhquIF46I6OsxlfUxOU_rBWFkrzl-R45JxybhSJ-TvfY6DyUPERENLgfbOux46uhl68HR-9XBHWxdTpn4wHYbsLBYr563za2pDD85TSLu94EOP8ZxuEGyRQ5HBjSqhD9b9-wdv6RbyJqzRO0P7IYPPr8nLFrqEb_bvGfl29flhvihubq-_zD_dFEYKnouyNBYUFxIUa6WQHEWDbLViSpa84UrODMwUw9ZUTSUqsBaxUcClVMAaW4kz8n7SDSk7nYzLaDYmeI8maz4GI2o1Qh8maAz1ccCUde-Swa4Dj2FIWslq512Wz5NCzOpZxXfGFxNpYkgpYqu3ccw3_h5d9a5BvW9QTw2OC-_20sOqR3vA_1c2Ah_3pwzb58WKiXUp468DDfGnHu9VUi--L_VyIa6_1ss7XYsnwO240A |
CitedBy_id | crossref_primary_10_1002_pro_3086 crossref_primary_10_1021_jp308315w crossref_primary_10_1002_cmdc_201000488 crossref_primary_10_3390_ijms21072407 crossref_primary_10_1074_jbc_M115_641134 crossref_primary_10_1007_s12033_014_9830_5 crossref_primary_10_1016_j_jmb_2012_03_001 crossref_primary_10_1042_BJ20121240 crossref_primary_10_1016_j_neuropharm_2017_06_030 crossref_primary_10_1021_acs_jcim_5b00312 crossref_primary_10_1371_journal_pone_0085183 crossref_primary_10_1038_s41598_022_06456_5 crossref_primary_10_1002_1873_3468_13921 crossref_primary_10_1007_s10863_011_9372_5 crossref_primary_10_1002_pro_2460 crossref_primary_10_1038_s41598_017_15997_z crossref_primary_10_1074_jbc_M112_371138 crossref_primary_10_1016_j_tips_2012_11_006 crossref_primary_10_1016_j_jsb_2016_02_004 crossref_primary_10_1002_pro_3636 crossref_primary_10_1016_j_biocel_2014_04_004 crossref_primary_10_1002_pro_2821 crossref_primary_10_1016_j_cell_2011_11_023 crossref_primary_10_1016_j_bbamem_2016_10_009 crossref_primary_10_1085_jgp_201110608 crossref_primary_10_1016_j_jmb_2010_06_019 crossref_primary_10_1124_mol_117_108373 crossref_primary_10_1016_j_ejmech_2014_06_028 crossref_primary_10_1093_protein_gzx054 crossref_primary_10_1371_journal_pone_0178238 crossref_primary_10_1371_journal_pone_0074347 crossref_primary_10_1021_acs_jpcb_8b11970 crossref_primary_10_1038_s41589_021_00844_0 crossref_primary_10_1085_jgp_201711946 crossref_primary_10_1007_s00018_016_2390_z crossref_primary_10_1038_s41598_018_22959_6 crossref_primary_10_1007_s00018_022_04671_x crossref_primary_10_1021_acs_jcim_0c01207 crossref_primary_10_1016_j_molmed_2011_10_003 crossref_primary_10_1074_jbc_M112_420489 crossref_primary_10_1007_s00018_014_1747_4 crossref_primary_10_1038_s41467_019_10714_y crossref_primary_10_3390_biom4020498 crossref_primary_10_1074_jbc_M115_665125 crossref_primary_10_1073_pnas_1315104110 crossref_primary_10_1007_s00360_012_0664_9 crossref_primary_10_1007_s00018_016_2384_x crossref_primary_10_1038_nsmb_2741 crossref_primary_10_1042_bse0500233 crossref_primary_10_1002_pro_479 crossref_primary_10_1007_s00018_016_2385_9 crossref_primary_10_1016_j_chembiol_2013_06_004 crossref_primary_10_1371_journal_pone_0015458 crossref_primary_10_1517_17460441_2013_788495 crossref_primary_10_1016_j_abb_2024_110050 crossref_primary_10_1016_j_biocel_2014_01_024 crossref_primary_10_1093_nar_gkq831 crossref_primary_10_3390_jor1030019 crossref_primary_10_1007_s00726_013_1613_y crossref_primary_10_1074_jbc_M110_131623 crossref_primary_10_1016_j_biochi_2015_01_010 crossref_primary_10_1007_s12551_014_0137_3 crossref_primary_10_1016_j_jmb_2014_07_026 crossref_primary_10_1096_fj_201801218RR crossref_primary_10_1016_j_bbrc_2019_08_121 crossref_primary_10_1016_j_jbc_2022_101615 crossref_primary_10_1515_hsz_2018_0470 crossref_primary_10_1016_j_bbamem_2018_02_006 crossref_primary_10_1016_j_pbiomolbio_2014_08_004 crossref_primary_10_1074_jbc_RA117_000819 crossref_primary_10_1002_pro_480 crossref_primary_10_1002_1873_3468_13997 |
Cites_doi | 10.1074/jbc.C700175200 10.1038/nrm1949 10.1074/jbc.M410968200 10.1007/s00424-006-0126-x 10.1073/pnas.0709388104 10.1042/BJ20061879 10.1016/j.abb.2008.03.033 10.1002/jmr.753 10.1126/science.2475911 10.1002/pro.5560050111 10.1038/nature04712 10.1038/nature05626 10.1006/abbi.1999.1656 10.1172/JCI117311 10.1038/nature05155 10.1002/1097-0134(20000815)40:3<389::AID-PROT50>3.0.CO;2-2 10.1038/nsmb1278 10.1007/s00210-005-0031-4 10.1042/BJ20050897 10.1038/nature03313 10.1085/jgp.116.2.163 10.1107/S090744490603575X 10.1016/j.molcel.2006.07.034 10.1038/sj.emboj.7600657 10.1126/science.1145950 10.1126/science.1168750 10.1016/S1097-2765(02)00576-2 10.1038/nsmb881 10.1085/jgp.200409174 10.1152/physrev.1999.79.1.S23 10.1126/science.1071142 10.1016/j.molcel.2003.08.004 10.1126/science.1133488 10.1006/jsbi.1999.4094 10.1107/S0907444994003112 10.1038/nature06264 10.1002/pmic.200600028 10.1074/jbc.M111713200 10.1038/sj.emboj.7600040 10.1016/B978-012352551-2/50030-5 10.1016/S0969-2126(01)00617-7 10.1074/jbc.M407434200 |
ContentType | Journal Article |
Copyright | The Author 2010. Published by Oxford University Press. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org 2010 |
Copyright_xml | – notice: The Author 2010. Published by Oxford University Press. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org 2010 |
CorporateAuthor | Argonne National Lab. (ANL), Argonne, IL (United States). Advanced Photon Source (APS) |
CorporateAuthor_xml | – name: Argonne National Lab. (ANL), Argonne, IL (United States). Advanced Photon Source (APS) |
DBID | BSCLL CGR CUY CVF ECM EIF NPM AAYXX CITATION 7X8 7QO 7TM 8FD FR3 P64 OTOTI |
DOI | 10.1093/protein/gzq004 |
DatabaseName | Istex Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef MEDLINE - Academic Biotechnology Research Abstracts Nucleic Acids Abstracts Technology Research Database Engineering Research Database Biotechnology and BioEngineering Abstracts OSTI.GOV |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef MEDLINE - Academic Engineering Research Database Biotechnology Research Abstracts Technology Research Database Nucleic Acids Abstracts Biotechnology and BioEngineering Abstracts |
DatabaseTitleList | Engineering Research Database MEDLINE MEDLINE - Academic |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
EISSN | 1741-0134 |
EndPage | 384 |
ExternalDocumentID | 1002367 10_1093_protein_gzq004 20150177 10.1093/protein/gzq004 ark_67375_HXZ_ZH3GM6ZR_6 |
Genre | Research Support, U.S. Gov't, Non-P.H.S Research Support, Non-U.S. Gov't Journal Article |
GroupedDBID | --- -E4 -~X .2P .GJ .I3 .ZR 0R~ 123 18M 1TH 29P 2WC 4.4 482 48X 53G 5RE 5VS 5WA 5WD 70D AABZA AACZT AAIMJ AAJKP AAJQQ AAMDB AAMVS AAOGV AAPNW AAPQZ AAPXW AARHZ AAUAY AAUQX AAVAP AAVLN AAWDT ABEJV ABEUO ABIXL ABKDP ABMNT ABNHQ ABNKS ABPTD ABQLI ABQTQ ABWST ABXVV ABZBJ ACFRR ACGFO ACGFS ACIWK ACMRT ACPRK ACUFI ACUTJ ACUTO ADBBV ADEYI ADEZT ADFTL ADGKP ADGZP ADHKW ADHZD ADIPN ADJQC ADOCK ADQBN ADRIX ADRTK ADVEK ADYVW ADZTZ ADZXQ AEGPL AEHUL AEJOX AEKSI AELWJ AEMDU AENZO AEPUE AETBJ AEWNT AFFNX AFFZL AFGWE AFIYH AFOFC AFRAH AGINJ AGKEF AGQXC AGSYK AHMBA AHXPO AIAGR AIJHB AJEEA AKHUL ALMA_UNASSIGNED_HOLDINGS ALUQC ANFBD APIBT APWMN AQDSO ARIXL ATGXG ATTQO AZFZN BAWUL BAYMD BCRHZ BEYMZ BQDIO BSCLL BSWAC BTRTY BVRKM C1A CAG CDBKE COF CS3 CZ4 DAKXR DIK DILTD D~K EBD EBS EE~ EJD ELUNK EMOBN F5P F9B FEDTE FHSFR FLUFQ FOEOM FOTVD FQBLK GAUVT GJXCC H13 H5~ HAR HH5 HVGLF HW0 HZ~ I-F IH2 IOX J21 KAQDR KBUDW KOP KQ8 KSI KSN M-Z M49 N9A NGC NLBLG NOMLY NOYVH NTWIH NU- NVLIB O0~ O9- OAWHX OBC OBOKY OBS OCZFY ODMLO OEB OES OJQWA OJZSN OK1 OPAEJ OVD OWPYF O~Y P2P PAFKI PB- PEELM PQQKQ Q1. Q5Y R44 RD5 RNI ROL ROX RUSNO RW1 RXO RZO SV3 TEORI TJX TLC TR2 W8F X7H YAYTL YKOAZ YXANX ZKX ~91 AASNB KC5 CGR CUY CVF ECM EIF NPM AAYXX CITATION 7X8 7QO 7TM 8FD FR3 P64 AABJS AABMN AAESY AAIYJ AANRK AAPBV ABPTK ACIMA ADEIU ADORX ADQLU AELNO AFXEN AGVJH AIKOY AIMBJ AKWXX ASMCH AWCFO AXUDD AYOIW AZQFJ BGYMP BHONS BYORX CASEJ DPORF DPPUQ OTOTI PQEST UMP |
ID | FETCH-LOGICAL-c531t-22cda7135a70f5351e39e0bb0752191758ca870efc49434addee97a1557a09d43 |
ISSN | 1741-0126 |
IngestDate | Fri May 19 01:41:18 EDT 2023 Fri Oct 25 04:13:31 EDT 2024 Fri Oct 25 22:21:59 EDT 2024 Thu Sep 26 16:25:44 EDT 2024 Tue Oct 15 23:36:25 EDT 2024 Wed Aug 28 03:20:15 EDT 2024 Wed Oct 30 09:51:41 EDT 2024 |
IsDoiOpenAccess | false |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 5 |
Keywords | regulatory insert NBD1 ABC transporter CFTR ΔF508 |
Language | English |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c531t-22cda7135a70f5351e39e0bb0752191758ca870efc49434addee97a1557a09d43 |
Notes | ArticleID:gzq004 ark:/67375/HXZ-ZH3GM6ZR-6 istex:AE8DEDFBDA2B031DCF89E0EB12D87FC3CCACD75E ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 USDOE |
OpenAccessLink | https://academic.oup.com/peds/article-pdf/23/5/375/17494208/gzq004.pdf |
PMID | 20150177 |
PQID | 733868414 |
PQPubID | 23479 |
PageCount | 10 |
ParticipantIDs | osti_scitechconnect_1002367 proquest_miscellaneous_754535122 proquest_miscellaneous_733868414 crossref_primary_10_1093_protein_gzq004 pubmed_primary_20150177 oup_primary_10_1093_protein_gzq004 istex_primary_ark_67375_HXZ_ZH3GM6ZR_6 |
PublicationCentury | 2000 |
PublicationDate | 2010-05-01 |
PublicationDateYYYYMMDD | 2010-05-01 |
PublicationDate_xml | – month: 05 year: 2010 text: 2010-05-01 day: 01 |
PublicationDecade | 2010 |
PublicationPlace | England |
PublicationPlace_xml | – name: England – name: United States |
PublicationTitle | Protein engineering, design and selection |
PublicationTitleAlternate | Protein Eng Des Sel |
PublicationYear | 2010 |
Publisher | Oxford University Press |
Publisher_xml | – name: Oxford University Press |
References | Rich ( key 20170523200433_GZQ004C36) 2005; 18 Wang ( key 20170523200433_GZQ004C43) 2007; 282 Hollenstein ( key 20170523200433_GZQ004C17) 2007; 446 Csanady ( key 20170523200433_GZQ004C9) 2005; 125 Dawson ( key 20170523200433_GZQ004C11) 2006; 443 Cheung ( key 20170523200433_GZQ004C8) 2008; 476 Riordan ( key 20170523200433_GZQ004C37) 1989; 245 Oswald ( key 20170523200433_GZQ004C31) 2006; 372 Smith ( key 20170523200433_GZQ004C40) 2002; 10 Procko ( key 20170523200433_GZQ004C34) 2006; 24 Lu ( key 20170523200433_GZQ004C27) 2000; 375 Chen ( key 20170523200433_GZQ004C7) 2003; 12 Aleksandrov ( key 20170523200433_GZQ004C1) 2002; 277 Atwell ( key 20170523200433_GZQ004C3) 2007; 30 Hvorup ( key 20170523200433_GZQ004C18) 2007; 317 Zaitseva ( key 20170523200433_GZQ004C46) 2005; 24 Ramaen ( key 20170523200433_GZQ004C35) 2005; 391 Linton ( key 20170523200433_GZQ004C23) 2007; 453 Ollero ( key 20170523200433_GZQ004C30) 2006; 6 Pinkett ( key 20170523200433_GZQ004C33) 2007; 315 Guggino ( key 20170523200433_GZQ004C14) 2006; 7 Janin ( key 20170523200433_GZQ004C19) 2007; 63 Yike ( key 20170523200433_GZQ004C45) 1996; 5 Chan ( key 20170523200433_GZQ004C6) 2000; 116 Rosenberg ( key 20170523200433_GZQ004C38) 2004; 279 Locher ( key 20170523200433_GZQ004C24) 2002; 296 Lovell ( key 20170523200433_GZQ004C26) 2000; 40 Lewis ( key 20170523200433_GZQ004C22) 2005; 280 Holland ( key 20170523200433_GZQ004C16) 2003 McRee ( key 20170523200433_GZQ004C28) 1999; 125 Sheppard ( key 20170523200433_GZQ004C39) 1999; 79 Vergani ( key 20170523200433_GZQ004C42) 2005; 433 Baker ( key 20170523200433_GZQ004C4) 2007; 14 Gadsby ( key 20170523200433_GZQ004C13) 2006; 440 CCP4. ( key 20170523200433_GZQ004C5) 1994; 50 Ward ( key 20170523200433_GZQ004C44) 2007; 104 Hanrahan ( key 20170523200433_GZQ004C15) 2003 Thibodeau ( key 20170523200433_GZQ004C41) 2005; 12 Cystic Fibrosis Foundation. ( key 20170523200433_GZQ004C10) 2006 DeLano ( key 20170523200433_GZQ004C12) 2002 Logan ( key 20170523200433_GZQ004C25) 1994; 94 Karpowich ( key 20170523200433_GZQ004C20) 2001; 9 Lewis ( key 20170523200433_GZQ004C21) 2004; 23 Oldham ( key 20170523200433_GZQ004C29) 2007; 450 Aller ( key 20170523200433_GZQ004C2) 2009; 323 Pereira ( key 20170523200433_GZQ004C32) 2007; 405 |
References_xml | – volume: 282 start-page: 33247 year: 2007 ident: key 20170523200433_GZQ004C43 publication-title: J. Biol. Chem. doi: 10.1074/jbc.C700175200 contributor: fullname: Wang – volume: 7 start-page: 426 year: 2006 ident: key 20170523200433_GZQ004C14 publication-title: Nat. Rev. Mol. Cell Biol. doi: 10.1038/nrm1949 contributor: fullname: Guggino – volume: 280 start-page: 1346 year: 2005 ident: key 20170523200433_GZQ004C22 publication-title: J. Biol. Chem. doi: 10.1074/jbc.M410968200 contributor: fullname: Lewis – volume: 453 start-page: 555 year: 2007 ident: key 20170523200433_GZQ004C23 publication-title: Pflugers Arch. doi: 10.1007/s00424-006-0126-x contributor: fullname: Linton – volume: 104 start-page: 19005 year: 2007 ident: key 20170523200433_GZQ004C44 publication-title: Proc. Natl Acad. Sci. USA doi: 10.1073/pnas.0709388104 contributor: fullname: Ward – volume: 405 start-page: 181 year: 2007 ident: key 20170523200433_GZQ004C32 publication-title: Biochem. J. doi: 10.1042/BJ20061879 contributor: fullname: Pereira – volume: 476 start-page: 95 year: 2008 ident: key 20170523200433_GZQ004C8 publication-title: Arch. Biochem. Biophys doi: 10.1016/j.abb.2008.03.033 contributor: fullname: Cheung – volume: 18 start-page: 431 year: 2005 ident: key 20170523200433_GZQ004C36 publication-title: J. Mol. Recognit. doi: 10.1002/jmr.753 contributor: fullname: Rich – volume: 245 start-page: 1066 year: 1989 ident: key 20170523200433_GZQ004C37 publication-title: Science doi: 10.1126/science.2475911 contributor: fullname: Riordan – volume: 5 start-page: 89 year: 1996 ident: key 20170523200433_GZQ004C45 publication-title: Protein Sci. doi: 10.1002/pro.5560050111 contributor: fullname: Yike – volume: 440 start-page: 477 year: 2006 ident: key 20170523200433_GZQ004C13 publication-title: Nature doi: 10.1038/nature04712 contributor: fullname: Gadsby – volume: 446 start-page: 213 year: 2007 ident: key 20170523200433_GZQ004C17 publication-title: Nature doi: 10.1038/nature05626 contributor: fullname: Hollenstein – volume: 375 start-page: 7 year: 2000 ident: key 20170523200433_GZQ004C27 publication-title: Arch. Biochem. Biophys. doi: 10.1006/abbi.1999.1656 contributor: fullname: Lu – volume: 94 start-page: 228 year: 1994 ident: key 20170523200433_GZQ004C25 publication-title: J. Clin. Invest. doi: 10.1172/JCI117311 contributor: fullname: Logan – volume: 443 start-page: 180 year: 2006 ident: key 20170523200433_GZQ004C11 publication-title: Nature doi: 10.1038/nature05155 contributor: fullname: Dawson – volume: 40 start-page: 389 year: 2000 ident: key 20170523200433_GZQ004C26 publication-title: Proteins doi: 10.1002/1097-0134(20000815)40:3<389::AID-PROT50>3.0.CO;2-2 contributor: fullname: Lovell – volume: 14 start-page: 738 year: 2007 ident: key 20170523200433_GZQ004C4 publication-title: Nat. Struct. Mol. Biol. doi: 10.1038/nsmb1278 contributor: fullname: Baker – volume-title: Patient Registry 2006 Annual Report. year: 2006 ident: key 20170523200433_GZQ004C10 contributor: fullname: Cystic Fibrosis Foundation. – volume: 372 start-page: 385 year: 2006 ident: key 20170523200433_GZQ004C31 publication-title: Naunyn Schmiedebergs Arch. Pharmacol. doi: 10.1007/s00210-005-0031-4 contributor: fullname: Oswald – volume: 391 start-page: 481 year: 2005 ident: key 20170523200433_GZQ004C35 publication-title: Biochem. J. doi: 10.1042/BJ20050897 contributor: fullname: Ramaen – volume: 433 start-page: 876 year: 2005 ident: key 20170523200433_GZQ004C42 publication-title: Nature doi: 10.1038/nature03313 contributor: fullname: Vergani – volume: 116 start-page: 163 year: 2000 ident: key 20170523200433_GZQ004C6 publication-title: J. Gen. Physiol. doi: 10.1085/jgp.116.2.163 contributor: fullname: Chan – volume: 63 start-page: 1 year: 2007 ident: key 20170523200433_GZQ004C19 publication-title: Acta Crystallogr. D Biol. Crystallogr. doi: 10.1107/S090744490603575X contributor: fullname: Janin – volume: 24 start-page: 51 year: 2006 ident: key 20170523200433_GZQ004C34 publication-title: Mol. Cell doi: 10.1016/j.molcel.2006.07.034 contributor: fullname: Procko – volume: 24 start-page: 1901 year: 2005 ident: key 20170523200433_GZQ004C46 publication-title: Embo. J. doi: 10.1038/sj.emboj.7600657 contributor: fullname: Zaitseva – volume: 317 start-page: 1387 year: 2007 ident: key 20170523200433_GZQ004C18 publication-title: Science doi: 10.1126/science.1145950 contributor: fullname: Hvorup – volume: 323 start-page: 1718 year: 2009 ident: key 20170523200433_GZQ004C2 publication-title: Science doi: 10.1126/science.1168750 contributor: fullname: Aller – volume: 10 start-page: 139 year: 2002 ident: key 20170523200433_GZQ004C40 publication-title: Mol. Cell doi: 10.1016/S1097-2765(02)00576-2 contributor: fullname: Smith – volume-title: The PyMOL Molecular Graphics System. year: 2002 ident: key 20170523200433_GZQ004C12 contributor: fullname: DeLano – volume: 30 start-page: 2 year: 2007 ident: key 20170523200433_GZQ004C3 publication-title: Pediatr. Pulmonol. Suppl. contributor: fullname: Atwell – volume-title: ABC Proteins: From Bacteria to Man year: 2003 ident: key 20170523200433_GZQ004C16 contributor: fullname: Holland – volume: 12 start-page: 10 year: 2005 ident: key 20170523200433_GZQ004C41 publication-title: Nat. Struct. Mol. Biol. doi: 10.1038/nsmb881 contributor: fullname: Thibodeau – volume: 125 start-page: 43 year: 2005 ident: key 20170523200433_GZQ004C9 publication-title: J. Gen. Physiol. doi: 10.1085/jgp.200409174 contributor: fullname: Csanady – volume: 79 start-page: S23 year: 1999 ident: key 20170523200433_GZQ004C39 publication-title: Physiol. Rev. doi: 10.1152/physrev.1999.79.1.S23 contributor: fullname: Sheppard – volume: 296 start-page: 1091 year: 2002 ident: key 20170523200433_GZQ004C24 publication-title: Science doi: 10.1126/science.1071142 contributor: fullname: Locher – volume: 12 start-page: 651 year: 2003 ident: key 20170523200433_GZQ004C7 publication-title: Mol. Cell doi: 10.1016/j.molcel.2003.08.004 contributor: fullname: Chen – volume: 315 start-page: 373 year: 2007 ident: key 20170523200433_GZQ004C33 publication-title: Science doi: 10.1126/science.1133488 contributor: fullname: Pinkett – volume: 125 start-page: 156 year: 1999 ident: key 20170523200433_GZQ004C28 publication-title: J. Struct. Biol. doi: 10.1006/jsbi.1999.4094 contributor: fullname: McRee – volume: 50 start-page: 760 year: 1994 ident: key 20170523200433_GZQ004C5 publication-title: Acta Crystallogr. D Biol. Crystallogr. doi: 10.1107/S0907444994003112 contributor: fullname: CCP4. – volume: 450 start-page: 515 year: 2007 ident: key 20170523200433_GZQ004C29 publication-title: Nature doi: 10.1038/nature06264 contributor: fullname: Oldham – volume: 6 start-page: 4084 year: 2006 ident: key 20170523200433_GZQ004C30 publication-title: Proteomics doi: 10.1002/pmic.200600028 contributor: fullname: Ollero – volume: 277 start-page: 15419 year: 2002 ident: key 20170523200433_GZQ004C1 publication-title: J. Biol. Chem. doi: 10.1074/jbc.M111713200 contributor: fullname: Aleksandrov – volume: 23 start-page: 282 year: 2004 ident: key 20170523200433_GZQ004C21 publication-title: Embo J. doi: 10.1038/sj.emboj.7600040 contributor: fullname: Lewis – start-page: 589 volume-title: ABC Proteins: From Bacteria to Man year: 2003 ident: key 20170523200433_GZQ004C15 doi: 10.1016/B978-012352551-2/50030-5 contributor: fullname: Hanrahan – volume: 9 start-page: 571 year: 2001 ident: key 20170523200433_GZQ004C20 publication-title: Structure doi: 10.1016/S0969-2126(01)00617-7 contributor: fullname: Karpowich – volume: 279 start-page: 39051 year: 2004 ident: key 20170523200433_GZQ004C38 publication-title: J. Biol. Chem. doi: 10.1074/jbc.M407434200 contributor: fullname: Rosenberg |
SSID | ssj0026711 |
Score | 2.289073 |
Snippet | Upon removal of the regulatory insert (RI), the first nucleotide binding domain (NBD1) of human cystic fibrosis transmembrane conductance regulator (CFTR) can... |
SourceID | osti proquest crossref pubmed oup istex |
SourceType | Open Access Repository Aggregation Database Index Database Publisher |
StartPage | 375 |
SubjectTerms | ABC transporter BASIC BIOLOGICAL SCIENCES Binding Sites - genetics CFTR Cloning, Molecular Crystallization Cystic Fibrosis Transmembrane Conductance Regulator - chemistry Cystic Fibrosis Transmembrane Conductance Regulator - isolation & purification Dimerization DNA Primers - genetics FIBROSIS GENERAL AND MISCELLANEOUS//MATHEMATICS, COMPUTING, AND INFORMATION SCIENCE Humans Models, Molecular MUTANTS Mutation - genetics MUTATIONS NBD1 NUCLEOTIDES Protein Conformation Protein Structure, Tertiary - genetics PROTEINS regulatory insert REMOVAL RESIDUES RESOLUTION ΔF508 |
Title | Structures of a minimal human CFTR first nucleotide-binding domain as a monomer, head-to-tail homodimer, and pathogenic mutant |
URI | https://api.istex.fr/ark:/67375/HXZ-ZH3GM6ZR-6/fulltext.pdf https://www.ncbi.nlm.nih.gov/pubmed/20150177 https://search.proquest.com/docview/733868414 https://search.proquest.com/docview/754535122 https://www.osti.gov/biblio/1002367 |
Volume | 23 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3fa9swEBZZ-7KXsbFfWbshxtgeUreJJVvxYykrYbAxmhRCXoxsy6sZibvEgdKH_Yf7n3anU2y3KVu3F2OE5cS6T3cn6e47xt4FoUhlZHzPBLnwJLgAXpLDxMsDBQhSGdg8TBT-_CUcnctP02Da6fxqRS2tq-Qwvb4zr-R_pAptIFfMkv0HydYvhQa4B_nCFSQM13vJeGzJX9dLIo7VPeQJmWNyo92ZPzmdnPXyAty73gJZi8uqyAyuhG0eS1bOdbHAMjPQDzMbSHagmzOvKj0MLO1dlPMyK-ZNjCfWLy7h7xQYiYj1h9u-7VekfEAGkobiEPtlNkbEdl_Zojutk__jahOUPb7Q7QP-co05ihXV7iMChALwfFgfmWB8DlV3QzVVrwvmlaZa8eNLVFnL9qYGnce7TQ3Sw-DoQIPvWLLbbW7v0ylvSlZ2IA1amlhQQRZn1AXVoduyF8SldUnjA3ffrn_0qRzyTWruWyazDmSkI3wRuzfE1P8B2_VB7w2tnWioH0Nly0HX31ZziIoj1_-I-t_wkXZxul-Bx1DCSN9Kw9xaDVmvaPKYPXLLGX5M2HzCOmbxlP1scMnLnGvucMktLjnikltc8m1ccsIl1yvsR7g84G1U8hqVBxxAxRtMcsLkM3Z--nFyMvJcnQ8vBQtQeb6fZhpLRWrVzwMRDIyITD9JwJv1cTshGKYazIrJQatIIdEim0hp8ISV7keZFM_ZzqJcmJeM96M8ScPIpFIZqWSgjbQFUuVQZCoNsy77sBlZkJmlc4nvlmGXvbcDXz-ml98xCFIF8Wg6i2doo8LZWRx22R5KJgaPFWmXU8R_WiEXOJIjdtlbENhff4tv5BmDdscjO5hz5XoVKyGG4VAO_vQIrIFgzHy_y14QFOpf83E7c6DUq3t_9R572EzHfbYDcDGvweuukjcWy78BL-TfPg |
link.rule.ids | 230,315,783,787,888,27938,27939 |
linkProvider | ABC ChemistRy |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Structures+of+a+minimal+human+CFTR+first+nucleotide-binding+domain+as+a+monomer%2C+head-to-tail+homodimer%2C+and+pathogenic+mutant&rft.jtitle=Protein+engineering%2C+design+and+selection&rft.au=Atwell%2C+Shane&rft.au=Brouillette%2C+Christie+G.&rft.au=Conners%2C+Kris&rft.au=Emtage%2C+Spencer&rft.date=2010-05-01&rft.issn=1741-0126&rft.eissn=1741-0134&rft.volume=23&rft.issue=5&rft.spage=375&rft.epage=384&rft_id=info:doi/10.1093%2Fprotein%2Fgzq004&rft.externalDBID=n%2Fa&rft.externalDocID=10_1093_protein_gzq004 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1741-0126&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1741-0126&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1741-0126&client=summon |